Logo for Verve Therapeutics Inc

Verve Therapeutics Investor Relations Material

Latest events

Logo for Verve Therapeutics Inc

Study Update

Verve Therapeutics
Logo for Verve Therapeutics

Q3 2024

5 Nov, 2024
Logo for Verve Therapeutics

Q2 2024

8 Aug, 2024
Access the full event backlog
Slides, Transcripts, and Reports from 12,000+ public companies

Latest reports from Verve Therapeutics Inc

Access all reports
Verve Therapeutics Inc., founded in 2018, is a genetic medicines company focused on developing gene editing treatments for cardiovascular diseases. The company's flagship product, VERVE-101, is a single-course gene editing treatment designed to permanently inactivate the PCSK9 gene in the liver, with an aim to address cardiovascular conditions effectively. The company is headquartered in Cambridge, Massachusetts, and its shares are listed on the NASDAQ.